Literature DB >> 2747634

Identification of a polymorphically expressed member of the human cytochrome P-450III family.

S A Wrighton1, B J Ring, P B Watkins, M VandenBranden.   

Abstract

The human liver cytochrome P-450III family contains two highly related forms of cytochrome P-450 (P450), HLp and P450NF, that are expressed in the adult and a form, HLp2, that is expressed in the fetus. Immunoblot analyses of 46 liver specimens developed with an anti-HLp antibody demonstrated that, in addition to HLp, 11 specimens contained a previously undected higher molecular weight protein (termed HLp3). The expression of HLp3 did not correlate with the age, gender, smoking habits, or drug history of the patients. This protein was purified and found to be a P450 with a molecular weight of 52,000. Ouchterlony analyses using a polyclonal anti-HLp antibody yielded lines of partial identity between HLp3 and both HLp and HLp2. In addition, structural comparisons between these three proteins, including amino-terminal amino acid analyses and peptide mapping, indicated that HLp3, HLp2, and HLp are highly related but distinct proteins. In reconstituted systems, HLp and HLp3 were found to hydroxylate testosterone at the 6 beta and 2 beta positions. In microsomes, the rates of hydroxylation of testosterone at the 2 beta, 6 alpha, 6 beta, 15 beta, and 18 positions and the formation of an unknown were found to correlate with the levels of total HLp-related protein and these activities were inhibited by anti-HLp antibodies. In conclusion, our data demonstrate that HLp3 is a member of the human P450III family and is polymorphically expressed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747634

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

Authors:  C Balram; Qingyu Zhou; Yin Bun Cheung; Edmund J D Lee
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

Review 3.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

5.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 6.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 7.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

8.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Gene expression of cytochromes P450 in liver transplants over time.

Authors:  Mari Thörn; Stefan Lundgren; Gustaf Herlenius; Bo-Göran Ericzon; Lars Lööf; Anders Rane
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.